Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asandeutertinib - TYK Medicine/Qilu Pharmaceuticals

Next Previous
Drug Profile

Asandeutertinib - TYK Medicine/Qilu Pharmaceuticals

Alternative Names: Asandeutertinibum - TYK Medicines; Deuterated derivative of osimertinib - TYK Medicines; Deuterated osimertinib mesylate - TYK Medicines; Kardorisso; Osimertinib-d3; Runnor-9591; TY-9591

Latest Information Update: 02 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Changzhou Runnuo; Guangzhou Boji Pharmaceutical Biotechnology
  • Developer TYK Medicine
  • Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Ethers; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action ErbB receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer

Most Recent Events

  • 27 Aug 2026 Registered for Non-small cell lung cancer (Metastatic disease, First-line therapy, Late-stage disease) in China (PO) - First global approval
  • 27 Aug 2026 TYK Medicines announces intention to submit NDA to NMPA for Non-small cell lung cancer in first quarter of 2030
  • 27 Aug 2026 Efficacy data from a phase II ESAONA trial in Non-small cell lung cancer released by TYK Medicines

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top